POXEL.PA Stock - Poxel S.A.
Unlock GoAI Insights for POXEL.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $6.64M | $1.98M | $674,000 | $13.40M | $6.81M |
| Gross Profit | $3.66M | $1,000 | $2,000 | $13.34M | $6.81M |
| Gross Margin | 55.1% | 0.1% | 0.3% | 99.6% | 100.0% |
| Operating Income | $-3,662,000 | $-28,764,000 | $-21,890,000 | $-22,462,000 | $-29,847,000 |
| Net Income | $-18,305,000 | $-35,090,000 | $-31,398,000 | $-23,762,000 | $-31,858,000 |
| Net Margin | -275.8% | -1771.3% | -4658.5% | -177.4% | -468.1% |
| EPS | $-0.38 | $-0.91 | $-1.08 | $-0.83 | $-1.16 |
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
Visit WebsiteEarnings History & Surprises
POXEL.PAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 20, 2026 | — | — | — | — |
Q2 2025 | Apr 22, 2025 | — | — | — | — |
Q3 2024 | Aug 29, 2024 | — | $-0.17 | — | — |
Q2 2024 | Apr 29, 2024 | $-0.38 | $-0.28 | +26.6% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.42 | $-0.83 | -96.9% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.23 | $-0.62 | -168.1% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-0.61 | $-0.46 | +24.1% | ✓ BEAT |
Q2 2022 | May 17, 2022 | $-0.98 | $-0.55 | +44.0% | ✓ BEAT |
Q4 2021 | Oct 20, 2021 | $-0.31 | $-0.28 | +9.4% | ✓ BEAT |
Q2 2021 | Apr 21, 2021 | $-0.62 | $-0.70 | -12.2% | ✗ MISS |
Q4 2020 | Oct 20, 2020 | $-0.66 | $-0.45 | +31.2% | ✓ BEAT |
Q2 2020 | May 25, 2020 | — | $-0.77 | — | — |
Q4 2019 | Oct 7, 2019 | — | $-0.38 | — | — |
Q2 2019 | Apr 9, 2019 | — | $-0.23 | — | — |
Q4 2018 | Oct 16, 2018 | — | $0.28 | — | — |
Q1 2018 | Mar 23, 2018 | — | $-0.55 | — | — |
Q4 2017 | Oct 16, 2017 | — | $-0.42 | — | — |
Q2 2017 | May 4, 2017 | — | $-0.54 | — | — |
Q4 2016 | Oct 21, 2016 | — | $-0.63 | — | — |
Q2 2016 | Jun 20, 2016 | — | $-0.37 | — | — |
Latest News
Frequently Asked Questions about POXEL.PA
What is POXEL.PA's current stock price?
What is the analyst price target for POXEL.PA?
What sector is Poxel S.A. in?
What is POXEL.PA's market cap?
Does POXEL.PA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to POXEL.PA for comparison